Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 20/20 | 0.71 |
| ▸ | PTGDR | Q13258 | 6/20 | 0.71 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.51 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1952950 | 1.00 | PTGER4 (0.71) | PTGER4PTGDRPTGER2PTGER3 | |
| SCHEMBL196279 | 0.90 | PTGER4 (0.57) | PTGER4PTGDRPTGER2PTGER3 | |
| SCHEMBL26951177 | 0.89 | PTGER4 (0.55) | PTGER4PTGDRPTGER2 | |
| SCHEMBL28482882 | 0.89 | PTGER4 (0.58) | PTGER4PTGDRPTGER2 | |
| SCHEMBL1955609 | 0.89 | PTGER4 (0.58) | PTGER4PTGDRPTGER2 | |
| SCHEMBL12571984 | 0.89 | PTGER4 (0.56) | PTGER4PTGDRPTGER2 | |
| SCHEMBL24677001 | 0.88 | PTGER4 (0.54) | PTGER4PTGDRPTGER2 | |
| SCHEMBL196278 | 0.84 | PTGER4 (0.51) | PTGER4PTGDRPTGER2PTGER3 | |
| SCHEMBL13492636 | 0.84 | MMP13 (0.51) | PTGER4PTGDRPTGER2PTGER3 | |
| SCHEMBL1847632 | 0.84 | PTGER4 (0.66) | PTGER4PTGDRPTGER2PTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2320906-B1 | HETEROCYCLIC AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | BETA PHARMA CANADA INC (CA) | 2016-02-24 | — | — | EP | disclosed |
| EP-2320906-B1 | HETEROCYCLIC AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | BETA PHARMA CANADA INC (CA) | 2016-02-24 | — | — | EP | disclosed |
| US-8404736-B2 | Heterocyclic amide derivatives as EP4 receptor antagonists | BETA PHARMA CANADA INC. (CA) | 2013-03-26 | — | — | US | disclosed |
| US-8404736-B2 | Heterocyclic amide derivatives as EP4 receptor antagonists | BETA PHARMA CANADA INC. (CA) | 2013-03-26 | — | — | US | disclosed |
| US-8404736-B2 | Heterocyclic amide derivatives as EP4 receptor antagonists | BETA PHARMA CANADA INC. (CA) | 2013-03-26 | — | — | US | disclosed |
| US-20110136887-A1 | Heterocyclic Amide Derivatives as EP4 Receptor Antagonists | BETA PHARMA CANADA INC. (CA) | 2011-06-09 | — | — | US | disclosed |
| US-20110136887-A1 | Heterocyclic Amide Derivatives as EP4 Receptor Antagonists | BETA PHARMA CANADA INC. (CA) | 2011-06-09 | — | — | US | disclosed |
| EP-2320906-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | Beta Pharma Canada Inc. (CA) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010019796-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | CHEMIETEK, LLC (US) | 2010-02-18 | — | — | WO | disclosed |
| WO-2010019796-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | CHEMIETEK, LLC (US) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136887-A1 | Heterocyclic Amide Derivatives as EP4 Receptor Antagonists | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885PTGDR 6/4885PTGER2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.